HC Wainwright Issues Positive Estimate for SGMT Earnings

Sagimet Biosciences Inc. (NASDAQ:SGMT) – Investment analysts at HC Wainwright boosted their Q1 2025 EPS estimates for shares of Sagimet Biosciences in a research note issued on Thursday, March 13th. HC Wainwright analyst E. Arce now forecasts that the company will earn ($1.00) per share for the quarter, up from their prior forecast of ($1.08). HC Wainwright has a “Buy” rating and a $32.00 price objective on the stock. The consensus estimate for Sagimet Biosciences’ current full-year earnings is ($1.60) per share. HC Wainwright also issued estimates for Sagimet Biosciences’ Q2 2025 earnings at ($1.22) EPS, Q3 2025 earnings at ($1.31) EPS, Q4 2025 earnings at ($1.34) EPS, FY2025 earnings at ($4.86) EPS, FY2026 earnings at ($5.77) EPS, FY2027 earnings at ($5.44) EPS, FY2028 earnings at ($3.74) EPS and FY2029 earnings at ($2.29) EPS.

Sagimet Biosciences (NASDAQ:SGMT) last released its earnings results on Wednesday, March 12th. The company reported ($0.50) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.15.

Separately, Oppenheimer started coverage on Sagimet Biosciences in a research report on Friday, December 6th. They issued an “outperform” rating and a $30.00 target price for the company. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $23.00.

Sagimet Biosciences Trading Up 1.1 %

Shares of NASDAQ:SGMT opened at $3.78 on Monday. The firm has a market capitalization of $115.95 million, a PE ratio of -2.64 and a beta of 2.57. Sagimet Biosciences has a 1-year low of $2.39 and a 1-year high of $7.38. The business’s 50 day moving average is $4.22 and its 200-day moving average is $4.47.

Institutional Trading of Sagimet Biosciences

A number of hedge funds have recently modified their holdings of the company. Barclays PLC grew its holdings in Sagimet Biosciences by 14.3% during the third quarter. Barclays PLC now owns 57,230 shares of the company’s stock valued at $159,000 after purchasing an additional 7,178 shares during the period. Geode Capital Management LLC grew its holdings in shares of Sagimet Biosciences by 56.7% in the 3rd quarter. Geode Capital Management LLC now owns 252,298 shares of the company’s stock valued at $699,000 after buying an additional 91,246 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of Sagimet Biosciences by 66.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 72,017 shares of the company’s stock valued at $199,000 after buying an additional 28,690 shares during the period. Jacksonville Wealth Management LLC bought a new stake in shares of Sagimet Biosciences in the 4th quarter valued at $45,000. Finally, Stoneridge Investment Partners LLC raised its stake in Sagimet Biosciences by 22.2% during the 4th quarter. Stoneridge Investment Partners LLC now owns 20,836 shares of the company’s stock worth $94,000 after buying an additional 3,780 shares during the period. 87.86% of the stock is currently owned by institutional investors and hedge funds.

Sagimet Biosciences Company Profile

Sagimet Biosciences Inc, a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company’s lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis.